Impact of a change in antibiotic prophylaxis on total antibiotic use in a surgical intensive care unit

Infection

Volumn 38, Issue 1, 2010, Pages 19-24

  Meyer, E ^a   Schwab, F ^a   Pollitt, A ^b   Bettolo, W ^b   Schroeren Boersch, B ^c   Trautmann, M ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KLINIKUM STUTTGART   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; IMIDAZOLE DERIVATIVE; IMIPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TRIMETHOPRIM;

ADULT; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ARTICLE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PREOPERATIVE PERIOD; PSEUDOMONAS AERUGINOSA; SHUNTING; SURGICAL DRAINAGE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CEREBROSPINAL FLUID SHUNTS; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; INTENSIVE CARE; MIDDLE AGED;

EID: 77549087750     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-009-9115-2     Document Type: Article

References (19)

1. World Health Organisation: WHO global strategy for containment of antimicrobial resistance. World Health Organisation, Manila 2005.
2. K.R. Foster H. Grundmann 2006 Do we need to put society first? The potential for tragedy in antimicrobial resistance PLoS Med 3 177 180 10.1371/journal.pmed.0030029 (Pubitemid 43362869)
3. J.F. John Jr N.O. Fishman 1997 Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital Clin Infect Dis 24 471 485 9114203
4. M.H. Kollef S.T. Micek 2003 Strategies to prevent antimicrobial resistance in the intensive care unit Crit Care Med 33 1845 1853 10.1097/01.CCM.0000171849.04952.79
5. B. Ratilal J. Costa C. Sampaio 2006 Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts Cochrane Database Syst Rev 3 CD005365 1:STN:280:DC%2BD28vivFektg%3D%3D 16856095
6. A.K. Wagner S.B. Soumerai F. Zhang D. Ross-Degnan 2002 Segmented regression analysis of interrupted time series studies in medication use research J Clin Pharm Ther 27 299 309 10.1046/j.1365-2710.2002.00430.x 1:STN:280:DC%2BD38vhvFOnuw%3D%3D 12174032 (Pubitemid 34989269)
7. German Institute for Standardization (DIN): DIN 58940-4. Medical microbiology - methods for the determination of susceptibility of pathogens (except mycobacteria) to antimicrobial agents - part 4: evaluation classes of the minimum inhibitory concentration. Beuth Verlag, Berlin 1998.
8. F. Ansari K. Gray D. Nathwani G. Phillips S. Ogston C. Ramsay P. Davey 2003 Outcomes of an intervention to improve hospital antibiotic prescribing: interrupted time series with segmented regression analysis J Antimicrob Chemother 52 842 848 10.1093/jac/dkg459 1:CAS:528:DC%2BD3sXovVeku78%3D 14563900 (Pubitemid 37407814)
9. J. Zentner J. Gilsbach T. Felder 1995 Antibiotic prophylaxis in cerebrospinal fluid shunting: a prospective randomized trial in 129 patients Neurosurg Rev 18 169 172 10.1007/BF00383721 1:STN:280:DyaK287ltlGrug%3D%3D 8570063
10. L. Arnaboldi 1996 Antimicrobial prophylaxis with ceftriaxone in neurosurgical procedures: a prospective study of 100 patients undergoing shunt operations Chemotherapy 42 384 390 10.1159/000239470 1:CAS:528: DyaK28Xls1yru78%3D 8874978
11. E. Meyer F. Schwab D. Jonas H. Rueden P. Gastmeier F.D. Daschner 2004 Surveillance of antimicrobial use and antimicrobial resistance in intensive care units (SARI): 1. Antimicrobial use in German intensive care units Intensive Care Med 30 1089 1096 10.1007/s00134-004-2266-9 15045167 (Pubitemid 38833360)
12. J.A. Bosso P.D. Mauldin 2006 Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of Gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 50 2106 2112 10.1128/AAC.01359-05 1:CAS:528:DC%2BD28XlsVOiurw%3D 16723572 (Pubitemid 43807532)
13. P. Charbonneau J.J. Parienti P. Thibon M. Ramakers C. Daubin D. du Cheyron G. Lebouvier X. Le Coutour R. Leclercq 2006 French Fluoroquinolone Free (3F) Study Group: fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study Clin Infect Dis 42 778 784 10.1086/500319 1:CAS:528:DC%2BD28Xjslyntbo%3D 16477553 (Pubitemid 43363932)
14. D.L. Paterson 2004 Collateral damage from cephalosporin or quinolone antibiotic therapy Clin Infect Dis 38 [Suppl4] S341 S345 10.1086/382690 1:CAS:528:DC%2BD2cXlsVSqu7c%3D 15127367 (Pubitemid 38669889)
15. European Antimicrobial Resistance Surveillance System: EARSS Annual Report 2006. EARSS, Bilthoven 2007, pp 1-162.
16. A. Kola M. Holst I.F. Chaberny S. Ziesing S. Suerbaum P. Gastmeier 2007 Surveillance of extended-spectrum beta-lactamase-producing bacteria and routine use of contact isolation: experience from a three-year period J Hosp Infect 66 46 51 10.1016/j.jhin.2007.01.006 1:STN:280:DC%2BD2s3ntFelsQ%3D%3D 17350720 (Pubitemid 46657123)
17. D.L. Paterson R.A. Bonomo 2005 Extended-spectrum beta-lactamases: a clinical update Clin Microbiol Rev 18 657 686 10.1128/CMR.18.4.657-686.2005 1:CAS:528:DC%2BD2MXht1Wrsr%2FE 16223952 (Pubitemid 41504510)
18. M. Trautmann A. Pollitt U. Loh I. Synowzik W. Reiter J. Stecher M. Rohs U. May E. Meyer 2007 Implementation of an intensified infection control program to reduce MRSA transmissions in a German tertiary care hospital Am J Infect Control 35 643 649 10.1016/j.ajic.2007.04.280 18063128 (Pubitemid 350184162)
19. E. Meyer F. Schwab A. Pollitt M. Trautmann 2007 Resistance rates in ICUs: interpretation and pitfalls J Hosp Infect 65 84 85 10.1016/j.jhin.2006.09.009 1:STN:280:DC%2BD28jltVahug%3D%3D 17101192 (Pubitemid 44939365)